Medications and devices referenced include: SGLT2 Inhibitors Farxiga, Jardiance, Invokana, Steglatro, dapagliflozin GLP-1 Receptor Agonists / GIPs Mounjaro, Ozempic, Rybelsus, Trulicity, Victoza, liraglutide Anti-Obesity Medications Contrave, Lomaira, phentermine, Qsymia, Saxenda, Wegovy, Zepbound Continuous Glucose Monitors (CGMs) Device brands preferred by each payor Plans include major commercial plans/PBMs in Michigan (Aetna, BCBSM, Express Scripts, HAP, Priority Traditional, Priority Optimized, and United), as well as Medicare, Medicare Advantage plans (Aetna, BCBSM/BCN, HAP, Humana, Priority, United, and Wellcare), and Michigan Medicaid
Front Immunol 7 Aslam M, Ladilov Y (2022) Emerging role of cAMP/AMPK signaling
This is the format the Scripps study tested
This absorption difference may affect how quickly you see results and how sensitive your outcomes are to timing or digestive health